AstraZeneca Sees Potential for AI Beyond Drug Discovery

Dow Jones

Jul 27

1249 GMT - While many artificial-intelligence startups are exploring the technology's potential to find new drugs, AstraZeneca executives say the company is using it in other areas. AI is important in drug development, which entails large, expensive risks, AstraZeneca CEO Pascal Soriot says on a call with reporters. If AI can help fine-tune the design of a clinical trial to improve its chances of success, that could end up being a big benefit, Soriot says. The U.K. drugmaker is also using AI to improve productivity across the business, in areas like regulatory submissions, CFO Aradhana Sarin says on the call. AstraZeneca doesn't expect any direct impact on jobs from AI as its portfolio continues to grow, Sarin adds. Shares rise 1.2%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 27, 2026 08:50 ET (12:50 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2654048871"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2654048871\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2654048871?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654048871","market":"sg","top_or_hot":-1,"title":"AstraZeneca Sees Potential for AI Beyond Drug Discovery","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1249 GMT - While many artificial-intelligence startups are exploring the technology's potential to find new drugs, AstraZeneca executives say the company is using it in other areas. AI is important in drug development, which entails large, expensive risks, AstraZeneca CEO Pascal Soriot says on a call with reporters. If AI can help fine-tune the design of a clinical trial to improve its chances of success, that could end up being a big benefit, Soriot says. The U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker is also using AI to improve productivity across the business, in areas like regulatory submissions, CFO Aradhana Sarin says on the call. AstraZeneca doesn't expect any direct impact on jobs from AI as its portfolio continues to grow, Sarin adds. Shares rise 1.2%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 27, 2026 08:50 ET (12:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Sees Potential for AI Beyond Drug Discovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Sees Potential for AI Beyond Drug Discovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-27 20:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1249 GMT - While many artificial-intelligence startups are exploring the technology's potential to find new drugs, AstraZeneca executives say the company is using it in other areas. AI is important in drug development, which entails large, expensive risks, AstraZeneca CEO Pascal Soriot says on a call with reporters. If AI can help fine-tune the design of a clinical trial to improve its chances of success, that could end up being a big benefit, Soriot says. The U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker is also using AI to improve productivity across the business, in areas like regulatory submissions, CFO Aradhana Sarin says on the call. AstraZeneca doesn't expect any direct impact on jobs from AI as its portfolio continues to grow, Sarin adds. Shares rise 1.2%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 27, 2026 08:50 ET (12:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2462157665.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2654048871","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654048871","pubTimestamp":1785156600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1249 GMT - While many artificial-intelligence startups are exploring the technology's potential to find new drugs, AstraZeneca executives say the company is using it in other areas. AI is important in drug development, which entails large, expensive risks, AstraZeneca CEO Pascal Soriot says on a call with reporters. If AI can help fine-tune the design of a clinical trial to improve its chances of success, that could end up being a big benefit, Soriot says. The U.K. drugmaker is also using AI to improve productivity across the business, in areas like regulatory submissions, CFO Aradhana Sarin says on the call. AstraZeneca doesn't expect any direct impact on jobs from AI as its portfolio continues to grow, Sarin adds. Shares rise 1.2%.  Dow Jones NewswiresJuly 27, 2026 08:50 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","AIPO":"Defiance AI and Power Infrastructure ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","BK4007":"制药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","AGIX":"通用人工智能 ETF-AGIX","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","AZNH":"ASTRAZENECA PLC ADRhedged","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","BK4588":"碎股","ARTY":"ISHARES FUTURE AI & TECH ETF","QTOC":"Innovator Growth Accelerated Plus ETF - October","BK4585":"ETF&股票定投概念","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","AZN":"阿斯利康","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","VTHR":"Vanguard Russell 3000 ETF","BK4568":"美国抗疫概念","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC"},"translate_title":"阿斯利康看到了药物发现之外的人工智能潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIPO":1.5,"AZNH":0.6,"CHAT":1.5,"QTOC":1.5,"ARTY":1.5,"AGIX":1.5,"AZN":0.9,"VTHR":1.5},"content_text":"1249 GMT - While many artificial-intelligence startups are exploring the technology's potential to find new drugs, AstraZeneca executives say the company is using it in other areas. AI is important in drug development, which entails large, expensive risks, AstraZeneca CEO Pascal Soriot says on a call with reporters. If AI can help fine-tune the design of a clinical trial to improve its chances of success, that could end up being a big benefit, Soriot says. The U.K. drugmaker is also using AI to improve productivity across the business, in areas like regulatory submissions, CFO Aradhana Sarin says on the call. AstraZeneca doesn't expect any direct impact on jobs from AI as its portfolio continues to grow, Sarin adds. Shares rise 1.2%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 27, 2026 08:50 ET (12:50 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}